One powerful, patented
platform – a multitude of potential therapeutic applications
scroll down
The unique promise of NKT cell therapies
Scalable, universal therapies via our proprietary ACUA Platform
APPIA’S Technology
Our allogeneic off-the-shelf therapy has the potential to produce thousands of doses of CAR-NKT-cells that can be frozen and waiting for the patient at the clinic.
CURRENT Standard
Autologous CAR-T therapies are individualized and produced one dose at a time through an expensive manufacturing process. This can be dependent on the health of the patient’s own immune cells, which can be varied.
The ACUA Difference: Harnessing the power of rare, potent cancer-fighting innate-like T cells
Most allogeneic cells are mature cells from donors. They are engineered, edited, and massively expanded. Massive expansion of mature cells can lead to cell exhaustion and underperformance.
Our proprietary process starts with healthy hematopoietic stem cells to drive differentiation to these subtypes of rare but potent innate-like T cells, like NKT and gamma delta T cells. As part of the ACUA differentiation process, they are engineered to be armed with chimeric antigen receptors (CARs) to target the cancer.
Once cryopreserved, these universal T cells are uniquely suited for off-the-shelf therapy for hematologic and solid cancers.
“There is tremendous potential to be explored in allogeneic cell therapies. The board and I look forward to working with this stellar team to create transformative cell therapies that will help patients and the physicians who treat them”